StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson TECVAYLI (teclistamab) by Quarter

TECVAYLI (teclistamab) — Worldwide currency (FX) impact YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson TECVAYLI (teclistamab): -0.7% in Q3 2026, down 2.1 pts from a year earlier.

Latest, Q3 2026
-0.7%
Period ended Sep 30, 2026
Change on a year earlier
-2.1 pts
1.4% in Q3 2025
History
11 quarters
Since Q1 2024
Sources
11
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 312 | 177 | 76.6 | 77.3 | (0.7)”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTECVAYLI (teclistamab) — Worldwide currency (FX) impact YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 2026-0.7%-2.1 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 20260.4%-0.3 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 20263.4%+5.1 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 20251.9%+4.1 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 20251.4%+2.2 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 20250.7%+1.3 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 2025-1.7%-127.7 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 2024-2.2%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 2024-0.8%–Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 2024-0.6%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 2024126.0%–Form 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗

Cite this data

StockData. (2026). Johnson & Johnson TECVAYLI (teclistamab) (%), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-tecvayli-fx-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.